Market Currents
Mylan (MYL -0.7%) receives final approval with 180 days of generic marketing exclusivity from...
-
Friday, August 17, 2012, 1:38 PM ETMylan (MYL -0.7%) receives final approval with 180 days of generic marketing exclusivity from the FDA for its Pioglitazone Tablets, the generic versions of Takeda Pharmaceutical's Actos Tablets and Actoplus Met Tablets. The pills are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
